Background: The impact of primary biliary cholangitis (PBC) on health-related quality of life (HRQOL) is poorly understood. The aim of this study was to compare HRQOL in Danish patients with PBC to the general population and to assess associations to clinical and laboratory data.
Methods: We conducted a single-centre, cross-sectional questionnaire study in patients with PBC using the SF-36 and EQ-5D-5L. Clinical and paraclinical data were obtained from patients' healthcare records. SF-36 scores were compared to an age- and gender-matched Danish general population. A general linear model was used to explore which variables were associated with main SF-36 scores.
Results: Sixty-nine patients with PBC were included. Compared to the Danish general population, patients with PBC had a significantly lower HRQOL in the domains bodily pain, general health, vitality, social functioning, mental health and mental component summary score. No clinical characteristics (gender, age at inclusion, concurrent autoimmune hepatitis, pruritus or cirrhosis) or biochemical markers were significantly associated with main SF-36 scores (physical and mental component summary).
Conclusions: The study is the first to report on HRQOL in a well-characterized PBC patient population from Denmark. Danish patients with PBC had a significantly impaired HRQOL compared to the general population with the greatest impairment in mental aspects. Reductions in HRQOL were independent of clinical characteristics and biochemical markers why HRQOL should be considered as an independent outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S2724-5985.23.03206-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of deep response to ursodeoxycholic acid in primary biliary cholangitis - should it be the new clinical standard?
Curr Opin Gastroenterol
January 2025
Schiff Center for Liver Diseases, University of Miami Miller School of Medicine.
Purpose Of Review: This review explores the emerging concept of "deep response" in primary biliary cholangitis (PBC), defined by the normalization of biochemical markers, particularly alkaline phosphatase and bilirubin. It examines its potential as a new standard for disease management and its implications for long-term patient outcomes, health policies, and clinical decision-making.
Recent Findings: Recent studies suggest that achieving a deep response significantly improves long-term outcomes in some patients with PBC.
[Primary hepatic diffuse large B-cell lymphoma developed in a patient with primary biliary cholangitis].
Rinsho Ketsueki
January 2025
Department of Hematology, Kochi Medical School Hospital, Kochi University.
Primary hepatic lymphoma (PHL) is a lymphoproliferative disorder confined to the liver, with no evidence of lymphomatous involvement in other organs. Here, we report a case of diffuse large B-cell lymphoma (DLBCL)-type PHL in a patient with a long history of primary biliary cholangitis (PBC) and Sjögren's syndrome (SS). A 78-year-old woman presented with epigastralgia and was found to have a solitary liver tumor by contrast-enhanced computed tomography (CT).
View Article and Find Full Text PDFProbing the Effects of Multisite Mutations in the Lipoic Acid Region of the BCOADC-E2 Protein.
Int J Mol Sci
December 2024
College of Environmental Science and Engineering, Yangzhou University, Yangzhou 225127, China.
Primary biliary cholangitis (PBC) is a chronic disease, the prevalence of which has been increasing in recent years. And the prevalence of patients who test negative with existing diagnostic techniques remains high. It was found that the antigenic BCOADC-E2 protein could detect patients with a negative original test.
View Article and Find Full Text PDFComparison of Clinical and Pathologic Features of Antimitochondrial Antibodies-negative Primary Biliary Cirrhosis and Cholestatic Type Drug-induced Liver Injury.
J Clin Gastroenterol
December 2024
Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Aim: To compare the respective clinical and pathologic features of antimitochondrial antibodies-negative (AMA-negative) primary biliary cirrhosis (PBC) and cholestatic type drug-induced liver injury (DILI) for clinical differential diagnosis.
Patients And Methods: Clinical data from 23 patients with AMA-negative PBC and 39 patients with cholestatic type DILI, treated at our hospital between January 2013 and January 2024, were collected and retrospectively analyzed.
Results: The cholestatic type DILI group exhibited a higher incidence of malaise and abdominal pain compared with the AMA-negative PBC group.
Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.
Am J Psychiatry
January 2025
Department of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York (Pagni, Zeifman, Mennenga, Carrithers, Goldway, O'Donnell, Ross, Bogenschutz); School of Life Sciences, Arizona State University, Tempe (Mennenga); Department of Psychology, New York University, New York (Goldway); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Bhatt).
Article Synopsis
- The study explored how psilocybin-assisted therapy (PAT) impacts personality traits in people with alcohol use disorder (AUD), hypothesizing it would reduce trait impulsiveness and improve drinking behavior.
- Eighty-four AUD patients were divided into two groups (psilocybin vs. placebo) and assessed for changes in personality traits over time, finding significant personality shifts in the psilocybin group, including reduced neuroticism and increased openness.
- The results indicated that lower impulsiveness correlated with decreased alcohol consumption, particularly among those who drank at risk before treatment, pointing to potential benefits of PAT in addressing both personality and drinking behaviors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!